Straumann Holding AG

In Q2 2026, Straumann reported revenue of CHF 707 million, organic growth of 8.5%, and reported growth of 5.9% in Swiss francs. For the first half, revenue was around CHF 1.4 billion, with organic growth of 7.8%. Core gross profit in H1 was CHF 972 million, with a core gross margin of 70.5%; core EBIT was CHF 355 million with a margin of 25.7% including currency effects, or 26.9% at constant 2025 exchange rates. Core net profit was CHF 262 million, and free cash flow was CHF 169 million, up 49% year over year. For the full year 2026, management reiterated expectations for high single-digit organic revenue growth and core EBIT margin improvement of around 140 to 170 basis points at constant 2025 exchange rates.

Guillaume Daniellot said the company is in a strong position, with a clear strategy that is already delivering results, and emphasized that the half-year acceleration showed broad-based strength across regions. He highlighted the perform-and-transform strategy, saying Straumann is strengthening its core implant business while investing in adjacent growth areas like clear aligners, imaging and CAD/CAM. His tone was confident and upbeat on the business, while also being reflective about the planned CEO handover at year-end and the value of a smooth transition.

Isabelle Adelt said H1 core gross margin was 70.5% and explained that productivity and mix helped, while U.S. tariffs reduced margin by 60 basis points and a one-time Villeret equipment write-down reduced it by 30 basis points. She said core EBIT reached CHF 355 million, with 130 basis points of efficiency gains more than offsetting gross margin effects, and noted core operating expenses improved by about 130 basis points as a percentage of revenue. She also highlighted CHF 169 million of free cash flow, capital expenditure of CHF 74 million or 5.4% of revenue versus CHF 113 million last year, cash and cash equivalents of CHF 381 million, and a net cash position of CHF 350 million. On capital allocation, she said the priorities remain reinvestment for growth, a strong balance sheet for M&A flexibility, and maintaining and increasing dividends.

Analysts focused heavily on the CEO transition, asking why the change is happening now, why the board chose an external candidate, and what Christopher Norbye will bring despite limited recent healthcare experience. Guillaume said the timing reflects a planned, smooth transition after a long tenure, and that the board wanted broad functional and geographic experience; he added that Norbye agrees with the midterm guidance and that the leadership team is aligned. Questions also centered on China/VBP 2.0, and management said they are not seeing a change in ordering patterns, expect only limited ASP downside because private-market pricing is already lower, and believe local manufacturing plus multi-brand positioning can help them gain share. Another focus was digital growth and margins: management said SIRIOS X3 and the broader scanner ecosystem are driving strong adoption, particularly in North America, and that some of the margin upside is structural but part of it also reflects tariff and VBP timing benefits.